Inclusion Body Myositis (IBM)

Newly Diagnosed?

If you or a loved one has just been diagnosed with IBM, you probably have a lot of questions. Here's where to start:

• Understand your type of IBM — sporadic, familial, or hereditary
• Learn about disease stages — what to expect and how to prepare
• Treatment options — what works, what doesn't, and clinical trials
• Safe exercises — walking, aquatic therapy, resistance training, and the TMA home program
• Early stage tips — exercise, energy conservation, and finding specialists
• Find support — The Myositis Association, clinical trials, and specialist directories

What is IBM?

Inclusion Body Myositis (IBM) is one of the idiopathic inflammatory myopathies (IIMs), a group of rare muscle diseases characterized by chronic, progressive muscle inflammation accompanied by muscle weakness. It is the most common inflammatory muscle disease in adults over 50. The "inclusion body" in its name refers to a histological finding of rimmed vacuoles — abnormal cellular structures containing aggregated proteins — visible in muscle tissue on biopsy.

IBM is distinguished from other inflammatory myopathies by the simultaneous presence of two pathological processes: an autoimmune inflammatory reaction where immune cells (particularly CD8+ T cells) invade muscle fibers, and a degenerative process characterized by protein misfolding, vacuolar degeneration, and abnormal intracellular protein accumulations including amyloid-beta, tau, TDP-43, and ubiquitinated proteins.

Key Characteristics

• Asymmetric weakness — Unlike other myopathies, IBM often affects muscles on one side more than the other
• Distal AND proximal weakness — Both thigh muscles (difficulty climbing stairs, rising from chairs) and forearm/hand muscles (difficulty gripping, buttoning shirts) are affected
• Slow progression — The disease progresses gradually over months to years
• Resistant to treatment — Unlike polymyositis and dermatomyositis, IBM does not respond well to corticosteroids or immunosuppressive drugs
• Dysphagia — Difficulty swallowing affects approximately 40-85% of patients
• Falls risk — Quadriceps weakness leads to frequent falls, which can cause serious injuries including hip and skull fractures

Common Misdiagnoses

Because IBM is rare and shares symptoms with other conditions, it is frequently misdiagnosed. If you've been told your symptoms are "just aging" or haven't responded to treatment, consider asking your doctor about IBM.

• "Just aging" / Sarcopenia — The most common misdiagnosis. Progressive weakness after 50 is often dismissed as normal aging
• Polymyositis — IBM is often initially diagnosed as polymyositis, but IBM doesn't respond to the steroid treatment that works for polymyositis
• ALS (Lou Gehrig's disease) — A terrifying misdiagnosis; IBM progresses much more slowly than ALS
• Fibromyalgia — Muscle pain, fatigue, and weakness overlap significantly
• Cervical spinal stenosis — Weak hands and falling can mimic spinal cord compression
• Statins side effects — Muscle weakness from statins may be attributed to the medication rather than underlying IBM

How IBM Affects the Body

IBM targets specific muscle groups in a characteristic pattern. In the lower body, the quadriceps (particularly the rectus femoris) and tibialis anterior are typically affected first, leading to difficulty with stairs, walking, and frequent tripping from foot drop. In the upper body, the deep finger flexors and wrist flexors weaken early, making tasks like gripping objects, turning keys, and buttoning shirts increasingly difficult.

As the disease progresses, swallowing muscles may also become involved, leading to dysphagia — difficulty with both solids and liquids. In advanced stages, respiratory muscles can weaken, potentially requiring ventilatory support.

Types of IBM

IBM encompasses several distinct forms, from the most common sporadic form to rare hereditary variants. Understanding which type you have is important for prognosis and management.

Disease Stages

IBM follows a slowly progressive course. While the rate of progression varies between individuals, the disease can be broadly characterized into early, middle, and advanced stages — each with distinct challenges and management strategies.

No Cure, But Hope

As of 2024, there are no FDA-approved treatments specifically for IBM. However, active research is underway exploring rapamycin, BCG vaccine immunotherapy, anti-amyloid therapies, and stem cell approaches. Physical therapy remains the cornerstone of management, and adaptive strategies can significantly improve quality of life.

Frequently Asked Questions